Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trialDavid Marín, Katayoun Rezvani, May Daher et al.|Nature Medicine|2024Cited by 452
Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPDMayra Shanley, Katayoun Rezvani|Cancer Cell|2024Cited by 79